ADALIMUMAB

Brand name:

• Hyrimoz®

Pharmaceutical company:

SANDOZ PTY LTD

Condition/indication:
(therapeutic use)

• Severe Crohn disease (CD) Moderate to severe ulcerative colitis (UC) Severe active juvenile idiopathic arthritis (JIA) Complex refractory fistulising Crohn disease (CD) Severe active rheumatoid arthritis (RA) Severe psoriatic arthritis (PsA) Ankylosing spondylitis (AS) Severe chronic plaque psoriasis (CPP) Moderate to severe hidradenitis suppurativa (HS)

PBAC Submission type:

New PBS listing (Category 4)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – July 2024

Related medicines:

--

Submission received for:

July 2024 PBAC meeting

Opportunity for consumer comment:

Open 03/04/2023 and close 29/05/2024 (see PBS Website)

PBAC meeting:

Held on 10/07/2024

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

16/09/2024

Lodgement of required documentation:

24/09/2024

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 10/10/2024

Status:

Finalised

Government processes:

Commenced on 11/11/2024

Medicine listed on the PBS:

01/01/2025 (see PBS schedule)

---